Balantidiasis Market Research Report - Global forecast till 2027

Balantidiasis Market Information: By Diagnosis (Physical Examination, Stool Examination, Sigmoidoscopy, Biopsy), By Treatment (Antibiotics, Appendectomy), By End User (Hospitals, Clinics, Diagnostic Centers)-Global Forecast Till 2027

ID: MRFR/Pharma/3303-HCR | February 2021 | Region: Global | 110 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.


Market Synopsis of the Global Balantidiasis Market

Balantidiasis, also known as Balantidium coli infection, is a disease caused by intestinal protozoan parasite Balantidium coli.  Being transmitted through the fecal-oral route, a person acquires the disease by ingesting infective cysts from food and water contaminated by feces. The disease mainly affects large intestine. Diarrhea, weight loss, dysentery, abdominal pain, nausea, and vomiting are common symptoms for balantidiasis. The diseases is found to be prevalent in the rural areas of the developed and developing countries due to the contamination of water by the fecal matter of pigs or humans. The best remedy for the prevention of the disease are maintaining proper conditions for clean and safe drinking water. Antibiotics are most widely used for the treatment of balantidiasis.


Rising prevalence of gastrointestinal disorders, increasing number of patients and availability of treatment of balantidiasis drives the growth of the market. Additionally, the lack of hygiene and sanitation in the rural areas of developing countries is one of the many factors which affect the spread of this disease. Furthermore, rising awareness about the diseases transmitted through fecal-oral route influences the market growth. Competition among existing market players restrict the entry of new players.


The global balantidiasis market is expected to grow at a CAGR of 2.1% during the forecast period.


Key Players in the Global Balantidiasis Market


Some of the key players in this market are Pfizer (U.S.), Abbott (U.S.), GlaxoSmithKline plc. (U.K), BD (U.S.), Sandoz International GmbH (Germany), Amneal Pharmaceuticals LLC. (U.S.), Akorn, Inc. (U.S.), and PharmaDerm, a division of Fougera Pharmaceuticals Inc. (U.S.).


Intended Audience



  • Drug Manufacturers

  • Drug Suppliers

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Segments                                                                                                                                            


The global balantidiasis market is segmented on the basis of diagnosis, treatment, and end user.


On the basis of diagnosis, the market is segmented into stool examination, sigmoidoscopy, biopsy, and others.


On the basis of treatment, the market is segmented into antibiotics, appendectomy, and others. Antibiotics segment is further divided into tetracycline, metronidazole, and others.


On the basis of end user, the market is segmented into hospitals, clinics, diagnostic centers, and others.


Regional Analysis of the Global Balantidiasis Market              


The market for balantidiasis is found to be steady in Americas. The disease is less prevalent in North America due to high quality standards, negligible number of cases, and hygienic environment. Furthermore, emphasis on healthy life style and prevention of communicable diseases also influence the growth of the market. The prevalence of the disease is found to the higher rural South America than North American countries.


In Europe, the prevalence of balantidiasis is found to be low. Rising importance of hygienic food products and water, rigorous quality checks, rising expenditure on healthcare, and availability of funds boost the growth of the market.


In Asia Pacific, the prevalence of balantidiasis is found increasing steadily as a result of increasing prevalence of colitis, chronic diarrhea, and, deep intestinal ulcerations and poor hygienic conditions in developing countries. The infection is found to be sub clinical leading to the development of diarrhea leading to the perforation of colon. Furthermore, poor healthcare system in developing countries boost the market growth. Furthermore, the burden of gastrointestinal diseases is attributed to an increase in age, high prevalence of H pylori and lifestyle changes with risk factors such as smoking and obesity. According to the data from GLOBOCAN, in 2012, the age-standardized rate (ASR) of incidence for Asia Pacific was 15.8 and mortality was 11.7 per 100,000. According to World Health Organization (WHO), the geriatric population in China in the year 2013 was 22.6 million which is expected to show a massive growth to 90.4 million in 2050.


The Middle East & African region has high prevalence of balantidiasis. The infection is mainly acquired due to ingestion of food and water contaminated by cysts. Furthermore, gastrointestinal diseases are a major cause of disability in the Middle East & Africa. In Africa, the market for balantidiasis is driven by rising demand for primary care services and improving healthcare system.


FIGURE 1: Global Balantidiasis Market by Region, 2016 (%)
Balantidiasis Market


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Global Balantidiasis Market, by Region



  • Americas


    • North America


      • US

      • Canada


    • Latin America


  • Europe


    • Western Europe


      • Germany

      • France

      • Italy

      • Spain

      • UK

      • Rest of Western Europe


    • Eastern Europe


  • Asia-Pacific


    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific


  • The Middle East & Africa


    • Middle East

    • Africa



Research Methodology
Balantidiasis Market-


Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


 



Frequently Asked Questions (FAQ) :

Balantidiasis market is expected to expand at 2.1% CAGR from 2018 to 2023.

Rising prevalence of gastrointestinal disorders, availability of treatments for balantidiasis, and a large patient pool are the biggest growth drivers of the global balantidiasis market.

APAC can display a robust growth rate for the global balantidiasis market till 2023.

The Middle East & Africa can fetch maximum revenue for the global balantidiasis market due to high prevalence of the disease in both these regions.

BD, Pfizer, GlaxoSmithKline plc., Abbott, Sandoz International GmbH, PharmaDerm, Amneal Pharmaceuticals LLC, and Akorn, Inc. are notable players of the global balantidiasis market.

Table of Content

1. Report Prologue

2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

6. Global Balantidiasis Market, by Diagnosis

6.1 Introduction

6.2 physical examination

6.2.1 Market Estimates & Forecast, 2020-2027

6.3 stool examination

6.3.1 Market Estimates & Forecast, 2020-2027

6.4 sigmoidoscopy

6.4.1 Market Estimates & Forecast, 2020-2027

6.5 biopsy

6.4.1 Market Estimates & Forecast, 2020-2027

7. Global Balantidiasis Market, by Treatment

7.1 Introduction

7.2 antibiotics

7.2.1 Market Estimates & Forecast, 2020-2027

7.3 Appendectomy

7.3.1 Market Estimates & Forecast, 2020-2027

8. Global Balantidiasis Market, by End User

8.1 Introduction

8.2 Hospitals

8.2.1 Market Estimates & Forecast, 2020-2027

8.3 Clinics

8.3.1 Market Estimates & Forecast, 2020-2027

8.4 Diagnostic Centers

8.4.1 Market Estimates & Forecast, 2020-2027

9. Global Balantidiasis Market, by Region

9.1 Introduction

9.2 Americas

9.2.1 North America

9.2.1.1 U.S.

9.2.1.1 Canada

9.2.2 South America

9.3 Europe

9.3.1 Western Europe

9.3.1.1 Germany

9.3.1.2 France

9.3.1.3 U.K.

9.3.1.4 Italy

9.3.1.5 Spain

9.3.1.6 Rest of Western Europe

9.3.2 Eastern Europe

9.4 Asia Pacific

9.4.1 Japan

9.4.2 China

9.4.3 India

9.4.4 Australia

9.4.5 Republic of Korea

9.4.6 Rest of Asia Pacific

9.5 The Middle East & Africa

9.5.1 United Arab Emirates

9.5.2 Saudi Arabia

9.5.3 Oman

9.5.4 Kuwait

9.5.5 Qatar

9.5.6 Rest of the Middle East & Africa

10 Company Landscape

10.1 Introduction

10.2 Market Share Analysis

10.3 Key Development & Strategies

10.3.1 Key Developments

11 Company Profiles

11.1 Pfizer

11.1.1 Company Overview

11.1.2 Product Overview

11.1.3 Financials

11.1.4 SWOT Analysis

11.2 Abbott

11.2.1 Company Overview

11.2.2 Product Overview

11.2.3 Financial Overview

11.2.4 Key Developments

11.2.5 SWOT Analysis

11.3 GlaxoSmithKline plc.

11.3.1 Company Overview

11.3.2 Product Overview

11.3.3 Financial Overview

11.3.4 Key Development

11.3.5 SWOT Analysis

11.4 BD

11.4.1 Company Overview

11.4.2 Product/Business Segment Overview

11.4.3 Financial Overview

11.4.4 Key Development

11.4.5 SWOT Analysis

11.5 Amneal Pharmaceuticals LLC.

11.5.1 Company Overview

11.5.2 Product Overview

11.5.3 Financial overview

11.5.4 Key Developments

11.6 Akorn, Inc.

11.6.1 Company Overview

11.6.2 Product Overview

11.6.3 Financial Overview

11.6.4 Key Developments

11.7 Sandoz International GmbH

11.7.1 Overview

11.7.2 Product Overview

11.7.3 Financials

11.7.4 Key Developments

11.7.5 SWOT Analysis

11.8 Others

12 MRFR Conclusion

12.1 Key Findings

12.1.1 From CEO’s View Point

12.1.2 Unmet Needs of the Market

12.2 Key Companies to Watch

12.3 Prediction of Pharmaceutical Industry

13 Appendix

LIST OF TABLES

Table 1 Balantidiasis Industry Synopsis, 2020-2027

Table 2 Global Balantidiasis Market Estimates and Forecast, 2020-2027, (USD Million)

Table 3 Global Balantidiasis Market by Region, 2020-2027, (USD Million)

Table 4 Global Balantidiasis Market by Diagnosis, 2020-2027, (USD Million)

Table 5 Global Balantidiasis Market by Treatment, 2020-2027, (USD Million)

Table 6 Global Balantidiasis Market by End Users, 2020-2027, (USD Million)

Table 7 North America Balantidiasis Market by Diagnosis, 2020-2027, (USD Million)

Table 8 North America Balantidiasis Market by Treatment, 2020-2027, (USD Million)

Table 9 North America Balantidiasis Market by End Users, 2020-2027, (USD Million)

Table 10 U.S. Balantidiasis Market by Diagnosis, 2020-2027, (USD Million)

Table 11 US Balantidiasis Market by Treatment, 2020-2027, (USD Million)

Table 12 US Balantidiasis Market by End Users, 2020-2027, (USD Million)

Table 13 Canada Balantidiasis Market by Diagnosis, 2020-2027, (USD Million)

Table 14 Canada Balantidiasis Market by Treatment, 2020-2027, (USD Million)

Table 15 Canada Balantidiasis Market by End Users, 2020-2027, (USD Million)

Table 16 South America Balantidiasis Market by Diagnosis, 2020-2027, (USD Million)

Table 17 South America Balantidiasis Market by Treatment, 2020-2027, (USD Million)

Table 18 South America Balantidiasis Market by End Users, 2020-2027, (USD Million)

Table 19 Europe Balantidiasis Market by Diagnosis, 2020-2027, (USD Million)

Table 20 Europe Balantidiasis Market by Treatment, 2020-2027, (USD Million)

Table 21 Europe Balantidiasis Market by End Users, 2020-2027, (USD Million)

Table 22 Western Europe Balantidiasis Market by Diagnosis, 2020-2027, (USD Million)

Table 23 Western Europe Balantidiasis Market by Treatment, 2020-2027, (USD Million)

Table 24 Western Europe Balantidiasis Market by End Users, 2020-2027, (USD Million)

Table 25 Eastern Europe Balantidiasis Market by Diagnosis, 2020-2027, (USD Million)

Table 26 Eastern Europe Balantidiasis Market by Treatment, 2020-2027, (USD Million)

Table 27 Eastern Europe Balantidiasis Market by End Users, 2020-2027, (USD Million)

Table 28 Asia Pacific Balantidiasis Market by Diagnosis, 2020-2027, (USD Million)

Table 29 Asia Pacific Balantidiasis Market by Treatment, 2020-2027, (USD Million)

Table 30 Asia Pacific Balantidiasis Market by End Users, 2020-2027, (USD Million)

Table 31 Middle East & Africa Balantidiasis Market by Diagnosis, 2020-2027, (USD Million)

Table 32 Middle East & Africa Balantidiasis Market by Treatment, 2020-2027, (USD Million)

Table 33 Middle East & Africa Balantidiasis Market by End Users, 2020-2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Balantidiasis Market

Figure 3 Segmentation Market Dynamics for Balantidiasis Market

Figure 4 Global Balantidiasis Market Share, by Diagnosis 2020

Figure 5 Global Balantidiasis Market Share, by Treatment 2020

Figure 6 Global Balantidiasis Market Share, by End Users, 2020

Figure 7 Global Balantidiasis Market Share, by Region, 2020

Figure 8 North America Balantidiasis Market Share, by Country, 2020

Figure 9 Europe Balantidiasis Market Share, by Country, 2020

Figure 10 Asia Pacific Balantidiasis Market Share, by Country, 2020

Figure 11 Middle East & Africa Balantidiasis Market Share, by Country, 2020

Figure 12 Global Balantidiasis Market: Company Share Analysis, 2020 (%)

Figure 13 Pfizer: Key Financials

Figure 14 Pfizer: Segmental Revenue

Figure 16 Pfizer: Geographical Revenue

Figure 17 Abbott: Key Financials

Figure 18 Abbott: Segmental Revenue

Figure 19 Abbott: Geographical Revenue

Figure 20 GlaxoSmithKline plc: Key Financials

Figure 21 GlaxoSmithKline plc: Segmental Revenue

Figure 22 GlaxoSmithKline plc: Geographical Revenue

Figure 23 BD: Key Financials

Figure 24 BD: Segmental Revenue

Figure 25 BD: Geographical Revenue

Figure 26 Amneal Pharmaceuticals LLC..: Key Financials

Figure 27 Amneal Pharmaceuticals LLC: Segmental Revenue

Figure 28 Amneal Pharmaceuticals LLC: Geographical Revenue

Figure 29 Akorn, Inc.: Key Financials

Figure 30 Akorn, Inc.: Segmental Revenue

Figure 31 Akorn, Inc.: Geographical Revenue

Figure 32 Sandoz International GmbH: Key Financials

Figure 33 Sandoz International GmbH: Segmental Revenue

Figure 34 Sandoz International GmbH: Geographical Revenue